Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry

Abstract

Objective

This study aimed to evaluate the impact of biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) on lipid profile and atherogenic index of plasma (AIP) in rheumatoid arthritis (RA) patients and to compare the occurrence of dyslipidemia between patients using bDMARDs, tsDMARDs, or conventional DMARDs (cDMARDs).

Methods

Data on lipid profile, AIP, and occurrence of dyslipidemia were collected from the Korean College of Rheumatology BIOlogics registry. A comparison was conducted between patients using bDMARDs (tumor necrosis factor (TNF)-α inhibitor, tocilizumab, abatacept), Janus kinase inhibitors (JAKis), and cDMARDs. The Kaplan-Meier method was used to compare the occurrence of dyslipidemia between groups, and hazard ratios (HR) were calculated using the cox proportional hazard method.

Results

The data of 917, 826, 789, 691, and 520 RA patients were eligible for analysis at the baseline, 1-year, 2-year, 3-year, and 4-year follow-ups, respectively. Baseline total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) were higher in the cDMARDs group, whereas AIP was comparable. During the 4-year follow-up, AIP was comparable between the groups. The occurrence of dyslipidemia did not show a significant difference when comparing the bDMARDs/tsDMARDs and cDMARDs groups (P=0.06) or the TNF-α inhibitor, tocilizumab, abatacept, JAKi, and cDMARD user groups (P=0.3). In the multivariate cox proportional hazard model, older age (HR=1.03, P=0.005) and concomitant hypertension (HR=2.21, P=0.013) were significantly associated with dyslipidemia occurrence.

Conclusion

Long-term use of bDMARDs and tsDMARDs is relatively safe with regard to lipid profile, AIP, and the occurrence of dyslipidemia in RA patients.

Key Points
• The use of bDMARDs and tsDMARDs did not increase the risk of dyslipidemia than cDMARDs use in patients with RA.
• AIP was comparable between bDMARDs user, tsDMARDs user, and cDMARDs user group in 4-year follow-up data.
• Based on the present study, the long-term use of bDMARDs or tsDMARDs did not significantly deteriorate atherogenic lipid profile nor an increased risk of dyslipidemia in patients with RA.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001. https://doi.org/10.1038/nrdp.2018.1

    Article  PubMed  Google Scholar 

  2. 2.

    Won S, Cho SK, Kim D, Han M, Lee J, Jang EJ, Sung YK, Bae SC (2018) Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization. Rheumatol Int 38:649–656. https://doi.org/10.1007/s00296-017-3925-9

    Article  PubMed  Google Scholar 

  3. 3.

    Widdifield J, Paterson JM, Huang A, Bernatsky S (2018) Causes of death in rheumatoid arthritis: how do they compare to the general population? Arthritis Care Res 70:1748–1755. https://doi.org/10.1002/acr.23548

    Article  Google Scholar 

  4. 4.

    Blum A, Adawi M (2019) Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev 18:679–690. https://doi.org/10.1016/j.autrev.2019.05.005

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Sodergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76:17–28. https://doi.org/10.1136/annrheumdis-2016-209775

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. Jama 320:1360–1372. https://doi.org/10.1001/jama.2018.13103

    Article  PubMed  Google Scholar 

  7. 7.

    Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Muller-Ladner U, Mysler EF, da Silva JAP, Poor G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2019-216655

  8. 8.

    Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, Gomez-Reino JJ (2015) Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 67:117–127. https://doi.org/10.1002/art.38894

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393:2303–2311. https://doi.org/10.1016/s0140-6736(19)30419-2

    Article  PubMed  Google Scholar 

  10. 10.

    Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL Jr, Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR (2013) Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum 65:1430–1438. https://doi.org/10.1002/art.37916

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Desai RJ, Eddings W, Liao KP, Solomon DH, Kim SC (2015) Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study. Arthritis Care Res 67:457–466. https://doi.org/10.1002/acr.22483

    CAS  Article  Google Scholar 

  12. 12.

    Min HK, Lee J, Ju JH, Park SH, Kwok SK (2020) Impact of TNF-α inhibitor on lipid profile and atherogenic index of plasma in axial spondyloarthritis: 2-year follow-up data from the Catholic Axial Spondyloarthritis COhort (CASCO). Clin Rheumatol 39:471–477. https://doi.org/10.1007/s10067-019-04767-z

    Article  PubMed  Google Scholar 

  13. 13.

    Crowson CS, Gabriel SE, Semb AG, van Riel P, Karpouzas G, Dessein PH, Hitchon C, Pascual-Ramos V, Kitas GD (2017) Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford) 56:1102–1110. https://doi.org/10.1093/rheumatology/kex038

    CAS  Article  Google Scholar 

  14. 14.

    Carmena R, Duriez P, Fruchart JC (2004) Atherogenic lipoprotein particles in atherosclerosis. Circulation 109:Iii2–Iii7. https://doi.org/10.1161/01.Cir.0000131511.50734.44

    Article  PubMed  Google Scholar 

  15. 15.

    Frohlich J, Dobiasova M (2003) Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 49:1873–1880

    CAS  Article  Google Scholar 

  16. 16.

    Dobiášová M (2017) Atherogenic impact of lecithin-cholesterol acyltransferase and its relation to cholesterol esterification rate in HDL (FER(HDL)) and AIP [log(TG/HDL-C)] biomarkers: the butterfly effect? Physiol Res 66:193–203. https://doi.org/10.33549/physiolres.933621

    Article  PubMed  Google Scholar 

  17. 17.

    Dobiasova M, Frohlich J (2001) The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 34:583–588

    CAS  Article  Google Scholar 

  18. 18.

    Cure E, Icli A, Ugur Uslu A, Aydogan Baykara R, Sakiz D, Ozucan M, Yavuz F, Arslan S, Cumhur Cure M, Kucuk A (2017) Atherogenic index of plasma may be strong predictor of subclinical atherosclerosis in patients with Behcet disease. Z Rheumatol 76:259–266. https://doi.org/10.1007/s00393-016-0141-z

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Uslu AU, Kucuk A, Icli A, Cure E, Sakiz D, Arslan S, Baykara RA (2017) Plasma atherogenic index is an independent indicator of subclinical atherosclerosis in systemic lupus erythematosus. Eurasian J Med 49:193–197. https://doi.org/10.5152/eurasianjmed.2017.17143

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Cure E, Icli A, Uslu AU, Sakiz D, Cure MC, Baykara RA, Yavuz F, Arslan S, Kucuk A (2018) Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis : AIP associate with cIMT in AS. Clin Rheumatol 37:1273–1280. https://doi.org/10.1007/s10067-018-4027-0

    Article  PubMed  Google Scholar 

  21. 21.

    Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73:e285–e350. https://doi.org/10.1016/j.jacc.2018.11.003

    Article  Google Scholar 

  22. 22.

    Hassan S, Milman U, Feld J, Eder L, Lavi I, Cohen S, Zisman D (2016) Effects of anti-TNF-alpha treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arthritis Res Ther 18:261. https://doi.org/10.1186/s13075-016-1148-1

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Di Minno MN, Ambrosino P, Peluso R, Di Minno A, Lupoli R, Dentali F (2014) Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-alpha blockers: a meta-analysis of prospective studies. Ann Med 46:73–83. https://doi.org/10.3109/07853890.2013.874661

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN (2017) Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxidative Med Cell Longev 2017:1273042. https://doi.org/10.1155/2017/1273042

    CAS  Article  Google Scholar 

  25. 25.

    Liu J, Yang R, Zhou M, Mao W, Li H, Zhao H, Wang S, Chen W, Dong J, He Q (2017) Fractional esterification rate of cholesterol in high-density lipoprotein associates with risk of coronary heart disease. Lipids Health Dis 16:162. https://doi.org/10.1186/s12944-017-0545-z

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Seung-Ki Kwok.

Ethics declarations

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki (1964 Declaration of Helsinki and its later amendments). Written informed consent was obtained from each patient. This study was approved by the Institutional Review Board of Konkuk University Medical Center (approval number: 2020-05-003). Informed consent was obtained from all participants.

Consent for publication

All authors agreed to publish the present article.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 31 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Min, H.K., Kim, HR., Lee, SH. et al. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry. Clin Rheumatol (2021). https://doi.org/10.1007/s10067-021-05613-x

Download citation

Keywords

  • Atherogenic index of plasma
  • Biologic disease-modifying antirheumatic drugs
  • Janus kinase inhibitor
  • Lipid profile
  • Rheumatoid arthritis